Join
Live feed
·
PRReleasevia Quantisnow
Lyell Immunopharma Inc. logo

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
LYEL· Lyell Immunopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LYEL (Lyell Immunopharma Inc.) and more on Quantisnow.